Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States
- PMID: 25320099
- PMCID: PMC6563919
- DOI: 10.1212/WNL.0000000000000987
Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States
Abstract
Objective: To assess the occurrence of narcolepsy after influenza vaccines used in the United States that contained the influenza A(H1N1)pdm09 virus strain.
Methods: A population-based cohort study in the Vaccine Safety Datalink with an annual population of more than 8.5 million people. All persons younger than 30 years who received a 2009 pandemic or a 2010-2011 seasonal influenza vaccine were identified. Their medical visit history was searched for a first-ever occurrence of an ICD-9 narcolepsy diagnosis code through the end of 2011. Chart review was done to confirm the diagnosis and determine the date of symptom onset. Cases were patients who met the International Classification of Sleep Disorders, 2nd edition, narcolepsy diagnostic criteria. We compared the observed number of cases after vaccination to the number expected to occur by chance alone.
Results: The number vaccinated with 2009 pandemic vaccine was 650,995 and with 2010-2011 seasonal vaccine was 870,530. Among these patients, 70 had a first-ever narcolepsy diagnosis code after vaccination, of which 16 had a chart-confirmed incident diagnosis of narcolepsy. None had their symptom onset during the 180 days after receipt of a 2009 pandemic vaccine compared with 6.52 expected, and 2 had onset after a 2010-2011 seasonal vaccine compared with 8.83 expected.
Conclusions: Influenza vaccines containing the A(H1N1)pdm09 virus strain used in the United States were not associated with an increased risk of narcolepsy. Vaccination with the influenza A(H1N1)pdm09 vaccine viral antigens does not appear to be sufficient by itself to increase the incidence of narcolepsy in a population.
© 2014 American Academy of Neurology.
Figures
Similar articles
-
Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1045-1053. doi: 10.1002/pds.4788. Epub 2019 May 6. Pharmacoepidemiol Drug Saf. 2019. PMID: 31062443
-
Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.J Autoimmun. 2014 May;50:1-11. doi: 10.1016/j.jaut.2014.01.033. Epub 2014 Feb 19. J Autoimmun. 2014. PMID: 24559657 Review.
-
Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action.Lancet Infect Dis. 2014 Mar;14(3):227-38. doi: 10.1016/S1473-3099(13)70238-X. Epub 2013 Dec 19. Lancet Infect Dis. 2014. PMID: 24360892 Review.
-
Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.Brain. 2013 Aug;136(Pt 8):2486-96. doi: 10.1093/brain/awt187. Brain. 2013. PMID: 23884811
-
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.Vaccine. 2013 Feb 6;31(8):1246-54. doi: 10.1016/j.vaccine.2012.12.015. Epub 2012 Dec 16. Vaccine. 2013. PMID: 23246544
Cited by
-
COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza.Vaccines (Basel). 2024 May 9;12(5):514. doi: 10.3390/vaccines12050514. Vaccines (Basel). 2024. PMID: 38793765 Free PMC article. Review.
-
Narcolepsy, autoimmunity, and influenza A H1N1 vaccination.Encephalitis. 2021 Apr;1(2):31-35. doi: 10.47936/encephalitis.2021.00010. Epub 2021 Mar 23. Encephalitis. 2021. PMID: 37469760 Free PMC article. Review.
-
Neurologic Complications With Vaccines: What We Know, What We Don't, and What We Should Do.Neurology. 2023 Oct 3;101(14):621-626. doi: 10.1212/WNL.0000000000207337. Epub 2023 Apr 25. Neurology. 2023. PMID: 37185124 Free PMC article.
-
Higher basophil count decreases narcolepsy risk: a Mendelian randomization study.Neurol Sci. 2022 Sep;43(9):5575-5580. doi: 10.1007/s10072-022-06123-7. Epub 2022 May 12. Neurol Sci. 2022. PMID: 35554757
-
Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.Vaccine. 2022 May 20;40(23):3150-3158. doi: 10.1016/j.vaccine.2022.04.037. Epub 2022 Apr 18. Vaccine. 2022. PMID: 35465977 Free PMC article.
References
-
- Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clinics in chest medicine 2010;31:371–381. - PubMed
-
- Longstreth WT Jr., Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep 2007;30:13–26. - PubMed
-
- Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004;5:37–41. - PubMed
-
- The MPA investigates reports of narcolepsy in patients vaccinated with Pandemrix [online] Available at: http://www.lakemedelsverket.se/english/All-news/NYHETER-2010/The-MPA-inv.... Accessed 07/15/2014.
-
- National Institute for Health and Welfare recommends discontinuation of Pandemrix vaccinations [online] Available at: http://www4.thl.fi/en_US/web/en/pressrelease?id=22930. Accessed 07/15/2014.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous